CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
APAC
CANADA

About Us

Conference

Partner With Us

  • Europe
    • US
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Biotech
    Cancer Immunotherapy
    Cell and Gene Therapy Companies
    Clinical Trial Management
    Drug Discovery and Development
    Genomics
    Therapeutics
    Women's Health
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    CDMO
    Clinical Laboratory Services
    CRO
    Supplements
  • Business Services
    Clinical Research Training
    Life Science Consulting
    Life Science Logistics
    Life Science Marketing
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Bormioli Pharma

Federico Piutti, Innovation Manager

An open Innovation Approach Applied to the Pharmaceutical Industry

Federico Piutti

Federico Piutti

Bormioli Pharma is a global pharmaceutical packaging manufacturer marketing glass and plastic vials, containers and closures in over 100 countries around the world. Featuring 9 plants in Italy, France and Germany, and over 1,300 employees, the company started an innovation program in early 2019 named Bormioli Pharma Invents, based on an Open Innovation approach.


The Open Innovation approach is a breakthrough for the pharma packaging industry, which has traditionally been bound to internal R&D departments and processes that are neither easily accessible nor open to communication with external stakeholders.


Open Innovation was first theorized by Henry Chesbrough in 2004. He described the innovation models of cutting-edge companies in the 80s and the 90s and identified a common path: “Open Innovation”. Instead of setting up an exclusive internal process for knowledge development, Chesbrough understood that companies found developing a distributed ecosystem to be more efficient, where know-how can be identified and developed in collaboration with internal and external players, using the internal know-how to generate additional value through new business models


The advantages are: a significant cost reduction coming from inbound open innovation, reducing development costs, and generating a new revenue stream from spin offs and licenses. All of these savings significantly change the Innovation ROI.


In 2019, Bormioli Pharma turned theory into practice. First, we identified four opportunities for growth in our industry, four strategic pillars that we repute to be the main drivers of change in the pharmaceutical primary packaging market. These are: usability, connectivity, traceability and sustainability.


We developed an Open Innovation System around these pillars, which combines internal R&D assets with external contributors, fostering collaboration projects and identifying common ways to generate value.


Collaboration is the core of our open innovation ecosystem. In our network value chain we involve players, such as end users, clients and partners, but also start-ups, Research Centers and Universities, relying on specific Innovation Hubs or accelerators to stay at the forefront of innovation.


This requires a radical change of mindset within the company. To do this, we have diffused an innovation culture within the company, actively involving all of our employees - regardless of their position - in communication activities and specific training courses, as well as inspiring corporate “evangelists” to be the voice of innovation, spreading it throughout the company.


We strongly believe in this inclusive approach, as anyone can have a good idea worth developing.


Yet, no good idea can encourage change if it is not met with action. We must make it happen. That’s what our innovation model aims to do, speeding up the process from market analysis to prototypes and industrialization.


We identified four opportunities for growth in our industry, four strategic pillars that we repute to be the main drivers of change in the pharmaceutical primary packaging market: usability, traceability, connectivity, sustainability


Firstly, we start with an investigation phase based on real, human needs. Then, we identify all of the possible innovative solutions that can address these needs through a Design Thinking approach, which also allows us to prioritize the most promising innovative solutions. The definition of a partner, the wrapping up of a concept and the first prototype design are the next steps.


A mock-up is then developed and continuously tested and analyzed in order to refine it and make it more adherent to the final product, through what we call a “Fast Factory” approach, inspired by the Lean Startup methodology. Finally, the prototype is run through a validation circle, with multiple tests by clients and end users to fine-tune response and better tackle consumers’ needs, before going through a proof-of-concept phase and, finally, industrialization.


This is our innovation flow that has allowed us to showcase several concepts and products so far – all well-received by the industry – reducing time-to-market and multiplying the R&D efforts of the company through the support of external stakeholders. That’s why we define our Open Innovation approach as a real enabler in our growth strategy


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review Europe
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review Europe. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesrevieweurope.com/leadership-perspective/an-open-innovation-approach-applied-to-the-pharmaceutical-industry-nwid-856.html